Advances in the DNA methylation hydroxylase TET1.

Biomark Res · 2021 · PMC8520278 · PMID 34656178

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

[ 53 ] found that patients with higher TET1 levels showed a trend towards increased response efficiency to EGFR inhibitors compared to patients with lower TET1 expression, but the trend was not significant ( p = 0.08).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.